CDH2 and melanoma: Metastatic melanomas exhibited a higher proportion of cases with elevated N-cadherin immunostaining scores (scores 3 and 4) in 14/17 cases (43.75%), compared to non-metastatic melanomas in 3/15 cases (18.75%), with a significant difference between the groups (p = 0.0269) (Figure 2).